EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

αvβ6-Integrin-Targeted Radiopharmaceuticals in Oncology: A Scoping Review of Diagnostic Imaging and Emerging Theranostic Applications

Saad Ruzzeh, Serin Moghrabi, Marwah Abdulrahman, Ahmed Saad Abdlkadir, Hongcheng Shi, Michael C. Kreissl, Mike Sathekge, Akram Al-Ibraheem

Pharmaceuticals · 02.11.2026 · 19 (11) · 1738

DOI: 10.3390/ph19111738 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Pharmaceuticals, online erschienen am 02.11.2026. Verfasst von Saad Ruzzeh und 7 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: αvβ6-integrin is an emerging target for molecular imaging and radioligand therapy in epithelial malignancies. We mapped human oncologic evidence for αvβ6-targeted radiopharmaceuticals.

Methods

PubMed/MEDLINE, Scopus, and Embase were searched through 1 September 2026. Human clinical studies and informative case-based reports of αvβ6-targeted imaging or therapy in oncologic and cancer-related settings were included. Study characteristics, tracers, comparators, validation methods, and clinical applications were charted and synthesized descriptively in accordance with PRISMA-ScR.

Results

Thirty-nine publications included an estimated 223 unique participants after accounting for probable cohort overlap. Thirty-seven addressed imaging and two described [177Lu]Therahexin-503 therapy in single patients. [68Ga]Ga-Trivehexin was the most frequently reported diagnostic tracer. Evidence was concentrated in pancreatic, lung, and head-and-neck cancers; other malignancies were sparsely represented. Tumor visualization was feasible across several tracer platforms, and selected reports suggest a potentially complementary role alongside [18F]FDG PET/CT, particularly for equivocal nodal or inflammatory findings. Imaging protocols and reference standards varied, and most publications were small or case-based. Conclusions: αvβ6-targeted PET is promising but investigational. Prospective disease-specific studies with standardized acquisition, histopathological validation, and clinically relevant outcomes are needed; neither objective response nor progression-free survival was reported in the two therapeutic cases, and efficacy and long-term safety remain unestablished.

Zitieren

APA

Ruzzeh, S., Moghrabi, S., Abdulrahman, M., Abdlkadir, A. S., Shi, H., Kreissl, M. C., Sathekge, M., & Al-Ibraheem, A. (2026). αvβ6-Integrin-Targeted Radiopharmaceuticals in Oncology: A Scoping Review of Diagnostic Imaging and Emerging Theranostic Applications. Pharmaceuticals, 19(11), 1738. https://doi.org/10.3390/ph19111738

Vancouver

Ruzzeh S, Moghrabi S, Abdulrahman M, Abdlkadir AS, Shi H, Kreissl MC, et al. αvβ6-Integrin-Targeted Radiopharmaceuticals in Oncology: A Scoping Review of Diagnostic Imaging and Emerging Theranostic Applications. Pharmaceuticals. 2026;19(11):1738. doi:10.3390/ph19111738

BibTeX
@article{Ruzzeh2026,
  author = {Ruzzeh, Saad and Moghrabi, Serin and Abdulrahman, Marwah and Abdlkadir, Ahmed Saad and Shi, Hongcheng and Kreissl, Michael C. and Sathekge, Mike and Al-Ibraheem, Akram},
  title = {αvβ6-Integrin-Targeted Radiopharmaceuticals in Oncology: A Scoping Review of Diagnostic Imaging and Emerging Theranostic Applications},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1738},
  doi = {10.3390/ph19111738}
}
Kostenlos starten →